Very recent investigations in mouse models of tauopathies and Alzheimer’s disease suggested regulation of the complement 3 receptor (C3aR), that is abundant on astrocytes and microglia, rather than C3 itself as a feasible target for therapies aiming to reduce gliosis and formation of A1-astrocytes. The gene discussed is C3AR1; the disease is Alzheimer disease.